Geron Dirección

Dirección controles de criterios 2/4

El CEO de Geron's es Chip Scarlett , nombrado en Sep 2011, tiene una permanencia de 12.58 años. compensación anual total es $4.92M, compuesta por 16% salario y 84% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.021% de las acciones de la empresa, por valor de $445.06K. La antigüedad media del equipo directivo y de la junta directiva es de 4.3 años y 8.3 años, respectivamente.

Información clave

Chip Scarlett

Chief Executive Officer (CEO)

US$4.9m

Compensación total

Porcentaje del salario del CEO	16.0%
Permanencia del CEO	12.7yrs
Participación del CEO	0.02%
Permanencia media de la dirección	4.4yrs
Promedio de permanencia en la Junta Directiva	8.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chip Scarlett en comparación con los beneficios de Geron?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$201m
Dec 31 2023	US$5m	US$787k	-US$184m
Sep 30 2023	n/a	n/a	-US$175m
Jun 30 2023	n/a	n/a	-US$171m
Mar 31 2023	n/a	n/a	-US$150m
Dec 31 2022	US$3m	US$761k	-US$142m
Sep 30 2022	n/a	n/a	-US$131m
Jun 30 2022	n/a	n/a	-US$117m
Mar 31 2022	n/a	n/a	-US$118m
Dec 31 2021	US$2m	US$736k	-US$116m
Sep 30 2021	n/a	n/a	-US$108m
Jun 30 2021	n/a	n/a	-US$101m
Mar 31 2021	n/a	n/a	-US$87m
Dec 31 2020	US$2m	US$714k	-US$76m
Sep 30 2020	n/a	n/a	-US$81m
Jun 30 2020	n/a	n/a	-US$76m
Mar 31 2020	n/a	n/a	-US$75m
Dec 31 2019	US$2m	US$690k	-US$69m
Sep 30 2019	n/a	n/a	-US$47m
Jun 30 2019	n/a	n/a	-US$37m
Mar 31 2019	n/a	n/a	-US$30m
Dec 31 2018	US$3m	US$667k	-US$27m
Sep 30 2018	n/a	n/a	-US$27m
Jun 30 2018	n/a	n/a	-US$28m
Mar 31 2018	n/a	n/a	-US$28m
Dec 31 2017	US$3m	US$644k	-US$28m

Compensación vs. Mercado: La compensación total de Chip($USD4.92M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD2.33M).

Compensación vs. Ingresos: La compensación de Chip ha aumentado mientras la empresa no es rentable.

CEO

Chip Scarlett (72 yo)

12.7yrs

Permanencia

US$4,924,092

Compensación

Dr. John A. Scarlett, also known as Chip, M.D., has been the Chief Executive Officer of Geron Corporation since joining in September 2011 and has been its President since January 5, 2012. Dr. Scarlett is C...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
John Scarlett	Chairman of the Board	12.7yrs	US$4.92m	0.021% $ 474.9k
Michelle Robertson	Executive VP	less than a year	US$2.47m	0% $ 0
Andrew Grethlein	Executive VP & COO	5.3yrs	US$2.42m	0.00038% $ 8.6k
Scott Samuels	Executive VP	less than a year	US$3.61m	0% $ 0
Aron Feingold	Vice President of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Shannon Odam	Senior VP & Chief People Officer	4.9yrs	sin datos	sin datos
Melissa A. Behrs	Executive VP of Business Operations & Chief Alliance Officer	17.3yrs	US$1.15m	sin datos
Anil Kapur	Executive VP of Corporate Strategy & Chief Commercial Officer	4.4yrs	US$1.05m	0.010% $ 231.0k
Edward Koval	Executive VP & Chief Business Officer	2.4yrs	sin datos	sin datos
Faye Feller	Executive VP & Chief Medical Officer	1.8yrs	sin datos	sin datos

4.4yrs

Permanencia media

57.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0IV3 se considera experimentado (4.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
John Scarlett	Chairman of the Board	12.7yrs	US$4.92m	0.021% $ 474.9k
Gaurav Aggarwal	Independent Director	less than a year	US$290.82k	0% $ 0
V. Lawlis	Independent Director	12.2yrs	US$360.90k	0% $ 0
Elizabeth O'Farrell	Lead Independent Director	5.2yrs	US$375.53k	0.0057% $ 127.8k
Robert Jay Spiegel	Independent Director	14yrs	US$350.90k	0.028% $ 623.4k
Susan Molineaux	Independent Director	11.7yrs	US$345.90k	0.022% $ 496.1k
John McDonald	Independent Director	1.7yrs	US$348.40k	0% $ 0
Dawn Bir	Independent Director	5.2yrs	US$343.12k	0% $ 0

8.4yrs

Permanencia media

65.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 0IV3 se considera experimentada (8.3 años de antigüedad promedio).

Geron Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Geron Corporation, Annual General Meeting, May 09, 2024

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Geron Corporation Announces Chief Financial Officer Changes, Effective September 25, 2023

Geron Corporation Announces Chief Financial Officer Changes, Effective September 25, 2023

Geron Corporation Announces Board Changes

Insufficient new directors

Recent updates

First quarter 2024 earnings released: US$0.092 loss per share (vs US$0.07 loss in 1Q 2023)

Geron Corporation to Report Q1, 2024 Results on May 02, 2024

Geron Corporation, Annual General Meeting, May 09, 2024

Geron Corporation has completed a Follow-on Equity Offering in the amount of $149.999995 million.

Geron Corporation Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Full year 2023 earnings released: US$0.32 loss per share (vs US$0.37 loss in FY 2022)

Geron Corporation to Report Q4, 2023 Results on Feb 28, 2024

Forecast to breakeven in 2026

Geron Announces 50% Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Geron Announces Publication in the Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Geron Corporation has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released: US$0.077 loss per share (vs US$0.10 loss in 3Q 2022)

Geron Corporation to Report Q3, 2023 Results on Nov 02, 2023

Geron Corporation Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS

Geron Corporation Announces Chief Financial Officer Changes, Effective September 25, 2023

Geron Corporation Announces Chief Financial Officer Changes, Effective September 25, 2023

Geron Corporation Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS

New minor risk - Share price stability

Second quarter 2023 earnings released: US$0.09 loss per share (vs US$0.07 loss in 2Q 2022)

Geron Corporation to Report Q2, 2023 Results on Aug 03, 2023

Geron Corporation Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS

Geron Corporation Announces Submission of New Drug Application to FDA for First-In-Class Telomerase Inhibitor Imetelstat

Geron Corporation Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS

Geron Corporation Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Geron Corporation Announces Board Changes

First quarter 2023 earnings released: US$0.07 loss per share (vs US$0.091 loss in 1Q 2022)

Geron Corporation Announces Five Abstracts Related to Imetelstat Accepts at European Hematology Association Annual Meeting

Geron Corporation to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.37 loss per share (vs US$0.35 loss in FY 2021)

Geron Corporation has completed a Follow-on Equity Offering in the amount of $198.121928 million.

Geron Corporation has completed a Follow-on Equity Offering in the amount of $198.121928 million.

Geron Corporation Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS

Geron Corporation Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients

Insufficient new directors

Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.081 loss in 3Q 2021)

Geron Corporation to Report Q3, 2022 Results on Nov 03, 2022

Geron Corporation Appoints John F. McDonald to Board of Directors

Geron Corporation Announces Update on Securities Class Action Lawsuit

Geron Corporation Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis

Second quarter 2022 earnings released: US$0.07 loss per share (vs US$0.09 loss in 2Q 2021)

Geron Corporation to Report Q2, 2022 Results on Aug 11, 2022

Geron Corporation Announces Executive Changes

Geron Corporation Announces Board Appointment

First quarter 2022 earnings released: US$0.091 loss per share (vs US$0.086 loss in 1Q 2021)

Geron Corporation to Report Q1, 2022 Results on May 09, 2022

Insufficient new directors

Insufficient new directors

Geron Corporation has completed a Follow-on Equity Offering.

Geron Corporation has completed a Follow-on Equity Offering in the amount of $75 million.

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Geron Corporation to Report Q4, 2021 Results on Mar 10, 2022

Third quarter 2021 earnings released: US$0.081 loss per share (vs US$0.062 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.09 loss per share (vs US$0.064 loss in 2Q 2020)

Geron Corporation Announces Publication of IMbark Phase 2 Data in Journal of Clinical Oncology

Geron Reports Two Presentations At Virtual European Hematology Association Annual Congress

Forecast to breakeven in 2025

Geron Announces Two Presentations At Upcoming European Hematology Association Annual Congress

First quarter 2021 earnings released: US$0.086 loss per share (vs US$0.082 loss in 1Q 2020)

Full year 2020 earnings released: US$0.28 loss per share (vs US$0.36 loss in FY 2019)

Revenue beats expectations

Geron Corporation to Report Q4, 2020 Results on Mar 11, 2021

Geron Corporation Announces Opening of IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media